Trial Profile

A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suvorexant (Primary)
Indications Insomnia
Focus Adverse reactions; Pharmacodynamics
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

31 Jul 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
31 Jul 2012 Actual patient number changed from 24 to 25 and actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
12 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com